

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

74975

ADMINISTRATIVE DOCUMENTS

APPROVAL SUMMARY
REVIEW OF PROFESSIONAL LABELING
DIVISION OF LABELING AND PROGRAM SUPPORT
LABELING REVIEW BRANCH

ANDA Number: 74-975

Date of Submission: August 24, 1998

Applicant's Name: Ranbaxy Laboratories Limited

Established Name: Acyclovir Capsules, 200 mg

APPROVAL SUMMARY (List the package size, strength(s), and date of submission for approval):

Do you have 12 Final Printed Labels and Labeling? Yes

Container Labels: 100s & 500s

Satisfactory in FPL as of 7/22/98 submission

Professional Package Insert Labeling:

Satisfactory in FPL as of 8/24/98 submission
Combined Insert (shared with ANDA 74-980)
Revisions needed post-approval:

Encourage the relocation of "Rx only" to the TITLE section.

BASIS OF APPROVAL:

Was this approval based upon a petition? Yes

What is the RLD on the 356(h) form: Zovirax® Capsules

NDA Number: 18-828

NDA Drug Name: Zovirax® Capsules

NDA Firm: Glaxo Wellcome

Date of Approval of NDA Insert and supplement #: May 29, 1998/
S-020

Has this been verified by the MIS system for the NDA?
Yes

Was this approval based upon an OGD labeling guidance? No

Other Comments:

The firm has proposed for a **combined package insert** for separate applications for acyclovir tablets 74-980) and capsules (74-975). Please note that these applications **must be approved at the same time**, or further revisions may be necessary prior to approval.

FOR THE RECORD:

1. Labeling review was based on the labeling of ZOVIRAX® (Glaxo Wellcome: revised; March 1997 and approved May 29, 1997).

2. Dispensing recommendations:

USP: Not USP [However, USP packaging and storage for acyclovir is "Preserve in tight containers].

PF: Preserve in tight containers. [Vol. 22, no.4/copy in file folder-1996]

NDA: Well-closed container as defined in the USP [Container]

ANDA: Dispense in a tight, light-resistant container. [Container]

Storage recommendations:

PF: Preserve in tight containers. [Vol. 22, no.4/copy in file folder-1996]

NDA: Store at 15° to 25°C (59° to 77°F) and protect from moisture. [Insert]
Store at 15° to 25°C (59° to 77°F). [Container]

ANDA: Store at 15° to 25°C (59° to 77°F) and protect from moisture. [Insert]

Store at 15° to 25°C (59° to 77°F) and protect from light and moisture. [Container]

We will **NOT** ask to delete the terms "light" and "light-resistant" from container labels. (See FTR #74946 in the file holder)

3. With respect to the previous comment (b)(ii) on "Pregnancy exposure registry..." in the last review, see FTR #74946 in the file holder and FTR #11 below.

4. DOSAGE AND ADMINISTRATION (Bioequivalence of dosage forms):

Refer to the previous comment (d) (iii) under INSERT. This comment in the last review is based on the FTR #74946 in the file holder.

5. Patents/Exclusivity

No patent and exclusivity. The firm's information is accurate.

6. Components/Composition

The list of inactive ingredients in the DESCRIPTION section is consistent with the firm's components and composition statement, [Vol. B.1.1, Section VII/p.18, 19, 20, 25 & 34].

7. Container/Closure

200 mg: 100s and 500s - Opaque white HDPE/non-CRC
[Vol. B1.2, Section XIV, p. 3]

8. The firm's capsule imprints described in the HOW SUPPLIED section are consistent with the firm's finished dosage form description. [Vol. B1.2, section XV, p.3 (also see, B1.1 section VII, p.18 &22)]

9. Manufacturing functions:

-Applicant's name: Ranbaxy laboratories Limited.
-Manufacturer's name: : Eli Lilly and company/Indianapolis, Indiana
[Vol. B1.1, section IX]

10. This ANDA shares the insert with ANDA 74-980 for acyclovir tablets.

11. The following information is from a previous review/reviewer FTR.

a. The insert mentions no food effect -

In another study in 6 volunteers, the influence of food on the absorption of acyclovir was not apparent.

Previous reviews of other BE studies have shown that food increases the AUC and Cmax by as much as 40 to 60% for both generic and reference product. Both these parameters were increased after food for the studies submitted to this ANDA as well. The DAVDP has been made aware of the food effect findings and a

In another study in 6 volunteers, the influence of food on the absorption of acyclovir was not apparent.

Previous reviews of other BE studies have shown that food increases the AUC and Cmax by as much as 40 to 60% for both generic and reference product. Both these parameters were increased after food for the studies submitted to this ANDA as well. The DAVDP has been made aware of the food effect findings and a recommendation to change the Zovirax® labeling has been made.

- b. It was decided in a meeting between OGD and DAVDP that the issue of generic firms participation in the Pregnancy Exposure Registry should be based on BW's decision. This decision was forwarded to the Division of Antiviral Drug Products on 5/1/96 - that generic products not be allowed to refer to the pregnancy registry.

Date of Submission: July 22, 1998

Date of Review: August 21, 1998

Reviewer:

/S/

9/8/98
Date:

Team Leader:

an an

Date:

/S/

9/9/98

cc:

ANDA 74-975
DUP/DIVISION FILE
HFD-613/CHolquist/JGrace (no cc)
X:\NEW\FIRMSNZ\ANBAXY\LTRS&REV\74975NA3.L
Review